# Neoadjuvant Treatment of Fulzerasib Plus Cetuximab N01 in KRAS G12C Mutated Locally Advanced Colorectal Cancer With or Without Resectable Metastases

Source: https://onco.cc/trials/nct07581912/  
OnCo record `nct07581912` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Fulzerasib in Colorectal cancer, run by Zhejiang University, now recruiting.

## Summary

Neoadjuvant Treatment of Fulzerasib Plus Cetuximab N01 in KRAS G12C Mutated Locally Advanced Colorectal Cancer With or Without Resectable Metastases is a phase 2 interventional study registered as NCT07581912 by Zhejiang University, with 40 participants planned, started 2026-04-30 and due to reach its primary completion in 2028-12. Interventions recorded: fulzerasib; cetuximab N01. Conditions recorded: Colorectal Cancer, KRAS G12C Mutant Advanced Solid Tumors, Fulzerasib, Cetuximab N01.

Linked to the drug Fulzerasib because the registry names it among its interventions and Colorectal cancer among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07581912
- Phase: 2
- Setting: Neoadjuvant Treatment of Fulzerasib Plus Cetuximab N01 in KRAS G12C Mutated Locally Advanced Colorectal Cancer With or Without Resectable Metastases
- Sponsor: Zhejiang University
- Enrolled: 40

## Sources

- ClinicalTrials.gov NCT07581912: https://clinicaltrials.gov/study/NCT07581912

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/)
- drugs: [Fulzerasib](https://onco.cc/drugs/fulzerasib/)

---
JSON: https://onco.cc/api/v1/entities/nct07581912.json